February 23, 2006
Transition Therapeutics Inc. announced on Tuesday the issuance of U.S. Patent No. 6,992,060 ("Prolonged efficacy of islet neogenesis therapy methods with a gastrin/CCK receptor ligand and an EGF receptor ligand composition in subjects with preexisting diabetes"), increasing its patent portfolio in this field of diabetes treatment to seven. This patent discloses methods of treating patients having insulin-insufficient diabetes and who are in need of islet neogenesis by delivering "both a gastrin receptor ligand and an EGF receptor ligand," a method of treatment claimed by the company in its patent to result in a "surprising long term remission of the diabetic condition." This patent supports Transition's main diabetes regenerative product, E1-I.N.T.™ (Islet Neogenesis Therapy), currently in Phase II clinical trials for the treatment of Type-1 and Type-2 diabetes.
Transition Therapeutics Press Release: LINK
U.S. Patent No. 6,992,060: LINK
Additional Information on Transition's I.N.T.™ Products: LINK
Transition Therapeutics Press Release: LINK
U.S. Patent No. 6,992,060: LINK
Additional Information on Transition's I.N.T.™ Products: LINK
0 comments:
Post a Comment